Clinical impact of gastric acid suppressing medication use on the efficacy of elrotinib and gefitinib in patients with advanced non-small cell lung cancer harboring EGFR mutations.
Yoshitaka Zenke
No relevant relationships to disclose
Kiyotaka Yoh
Consultant or Advisory Role - AstraZeneca (U)
Honoraria - AstraZeneca; Chugai Pharma
Shingo Matsumoto
Honoraria - Chugai Pharma
Shigeki Umemura
Research Funding - Chugai Pharma
Seiji Niho
Honoraria - AstraZeneca; Chugai Pharma
Koichi Goto
Consultant or Advisory Role - Chugai Pharma (U)
Honoraria - AstraZeneca; Chugai Pharma
Research Funding - AstraZeneca; Chugai Pharma
Hironobu Ohmatsu
No relevant relationships to disclose
Yuichiro Ohe
Honoraria - AstraZeneca; Chugai Pharma
Research Funding - AstraZeneca; Chugai Pharma